Ginkgo Bioworks Holdings, Inc. (DNA) stock
DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/301% below fair value
$9.61−0.62 (-6.06%)
Close on Nov 13, 2026Market cap $647.14MP/E –Yield –
Ginkgo Bioworks statistics
76 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 13, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.83
- 2.22
Enterprise valuationIndustry
- EV / Sales
- 4.30
- 2.57
Share statisticsIndustry
- Shares Change (YoY)
- 11.0%
- 10.8%
- Shares Change (QoQ)
- 1.23%
- 0.50%
- Shares Held by Institutions
- 53.7%
- 56.4%
Short sellingIndustry
- Short Interest
- 9M
- –
- Short Interest Change
- 14.4%
- -0.80%
- Short % of Shares Outstanding
- 14.1%
- 6.30%
- Days to Cover
- 3.85
- 5.15
Stock price statisticsIndustry
- 52-Week High
- $18.22
- –
- 52-Week Low
- $5.37
- –
- 20-Day Moving Average
- $10.81
- –
- 50-Day Moving Average
- $10.29
- –
- 200-Day Moving Average
- $8.64
- –
- Average True Range (14)
- $1.43
- –
- Price Change (1 Week)
- -14.9%
- -1.15%
- Price Change (1 Month)
- -18.3%
- -4.87%
- Price Change (3 Months)
- 38.9%
- -21.0%
- Price Change (6 Months)
- 24.6%
- -20.6%
- Price Change (YTD)
- 15.6%
- -23.6%
- Price Change (1 Year)
- 15.0%
- -22.4%
- Price Change (3 Years)
- -83.3%
- -29.5%
- Price Change (5 Years)
- -98.1%
- -77.9%
- Average Volume (10 Days)
- 3M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 0.93
- 0.70
- Relative Strength Index (14)
- 44.7
- 43.4
- Volatility (1 Year)
- 104.1%
- 80.1%
- Beta (5 Years)
- 2.73
- 1.07
MarginsIndustry
- Pretax Margin
- -212.7%
- -11.6%
- EBITDA Margin
- -164.4%
- -27.7%
- FCF Margin
- -132.7%
- -9.56%
Returns on capitalIndustry
- Return on Equity (ROE)
- -52.7%
- -49.9%
- Return on Assets (ROA)
- -23.5%
- -40.6%
- Return on Invested Capital (ROIC)
- -113.4%
- -32.9%
- Return on Capital Employed (ROCE)
- -30.4%
- -37.9%
Financial positionIndustry
- Current Ratio
- 4.72
- 3.30
- Quick Ratio
- 1.46
- 2.39
GrowthIndustry
- Revenue Growth (YoY)
- -13.2%
- 6.82%
- Revenue Growth (3Y CAGR)
- -29.1%
- 2.25%
- Revenue Growth (5Y CAGR)
- 17.3%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.12
- 0.40
- Revenue Per Employee
- $269.59K
- $429.29K
- Profits Per Employee
- -$517.59K
- -$689.41K
- Employee Count
- 485
- 74
- WACC
- 17.6%
- 10.2%
Income statement (TTM)Industry
- Pretax Income
- -$278.14M
- -$12.95M
Balance sheetIndustry
- Net Cash (Debt)
- $84.50M
- $17.76M
- Net Cash Per Share
- $1.25
- $0.80
- Equity (Book Value)
- $392.64M
- $53.89M
- Book Value Per Share
- $5.83
- $1.50
- Tangible Book Value
- $352.91M
- $27.13M
- Working Capital
- $244.99M
- $79.99M
Cash flow (TTM)Industry
- Capital Expenditures
- -$6.56M
- -$1.00M
- FCF Per Share
- -$2.58
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -38.8%
- -21.8%
- FCF Yield
- -26.8%
- -9.44%
Taxes and interestIndustry
- Income Tax
- -$866.00K
- $73.00K
Scores and fair valueIndustry
- Altman Z-Score
- -9.15
- 0.23
- Piotroski F-Score
- 3
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | DNA | S&P 500 | Difference | DNA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.3% | -3.0% | −15.2 pts | ||
| 3 months | +32.7% | -2.8% | +35.5 pts | ||
| Year to date | +15.6% | +11.5% | +4.2 pts | ||
| 1 year | +20.1% | +13.5% | +6.7 pts | ||
| 3 years | -81.2% | +77.7% | −158.9 pts | -42.7% | +21.1% |
| 5 years | -98.1% | +72.6% | −170.7 pts | -54.9% | +11.5% |
| 10 years | +2302.5% | +308.2% | +1994.3 pts | +37.4% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
9M DNA shares were sold short on Oct 30, 2026, up 14.4% from the previous report. At recent volumes it would take 3.9 days to buy them back. Over the last 20 sessions, 56.6% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 9,490,310 | +14.4% | 2,464,798 | 3.9 |
| Oct 15, 2026 | 8,294,322 | +13.4% | 4,411,666 | 1.9 |
| Sep 30, 2026 | 7,315,221 | +2.1% | 2,735,902 | 2.7 |
| Sep 15, 2026 | 7,166,128 | +4.4% | 994,763 | 7.2 |
| Aug 31, 2026 | 6,865,017 | +22.7% | 1,249,746 | 5.5 |
| Aug 14, 2026 | 5,596,447 | +5.3% | 1,317,261 | 4.3 |
| Jul 31, 2026 | 5,317,028 | +2.1% | 797,215 | 6.7 |
| Jul 15, 2026 | 5,208,417 | +0.9% | 1,049,442 | 5.0 |
| Jun 30, 2026 | 5,160,266 | +5.1% | 1,282,484 | 4.0 |
| Jun 15, 2026 | 4,907,539 | +7.6% | 1,481,867 | 3.3 |
| May 29, 2026 | 4,562,024 | +0.8% | 932,929 | 4.9 |
| May 15, 2026 | 4,524,898 | -13.5% | 1,651,622 | 2.7 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?